US Stock MarketDetailed Quotes

SYRE Spyre Therapeutics

Watchlist
  • 23.130
  • -0.030-0.13%
Close Dec 19 16:00 ET
  • 23.130
  • 0.0000.00%
Post 16:20 ET
1.36BMarket Cap-15.42P/E (TTM)

About Spyre Therapeutics Company

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe on December 16, 2013 and is headquartered in Waltham, MA.

Company Profile

SymbolSYRE
Company NameSpyre Therapeutics
Listing DateApr 7, 2016
Founded2013
CEODr. Cameron Turtle, D.Phil.
MarketNASDAQ
Employees30
Fiscal Year Ends12-31
AddressBuilding 17,221 Crescent Street,Suite 102B
CityWaltham
ProvinceMassachusetts
CountryUnited States of America
Zip Code02453
Phone1-617-651-5940
Websitehttp://www.spyre.com

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Cameron Turtle, D.Phil.
  • Director, President and Chief Executive Officer
  • 15.92M
  • Dr. Scott L. Burrows, M.D.
  • Chief Financial Officer and Principal Accounting Officer
  • 7.55M
  • Heidy King-Jones
  • Chief Legal Officer and Corporate Secretary
  • 6.59M
  • Jeffrey W. Albers, J.D.
  • Chairman of the Board
  • 433.57K
  • Dr. Sandra Milligan, J.D.
  • Director
  • --
  • Mark C. McKenna
  • Independent Director
  • --
  • Dr. Michael Henderson, M.D.
  • Independent Director
  • --
  • Peter Harwin
  • Independent Director
  • 661.28K
  • Laurie D. Stelzer, M.B.A.
  • Independent Director
  • 434.38K
  • Tomas Kiselak
  • Independent Director
  • 658.43K
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Symbol Mini Chart % Chg
Oracle
ORCL
+2.04%
NVIDIA
NVDA
+1.37%
Amazon
AMZN
+1.26%
Petroleo Brasileiro SA Petrobras
PBR
+0.86%
Apple
AAPL
+0.70%

Unlock the Full List